An observational study in Upper and/or Lower Limb Focal Spasticity, sponsored by Ipsen. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-21.
Sponsored by Ipsen · Observational
The aim of this retrospective study is to describe the real-world outcomes with the treatment of adult patients with Dysport® injections for focal upper limb spasticity (ULS) and/or focal lower limb spasticity (LLS) in NHS hospital settings in the United Kingdom (UK).
704 studies on the registry are indexed under Muscle Spasticity; 149 are open to participants now.
This study's enrollment of 123 is above the median of 60 across 162 observational studies indexed under Muscle Spasticity.
Browse Muscle Spasticity studies →Ipsen is the lead sponsor of 282 studies on the registry; 16 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 19 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
3-5 Secondary care centres in the UK
Exclusion Criteria:
Average total dose of AboBoNT-A for focal upper limb and/or lower limb spasticity per treatment session
Time frame: From baseline (when each patient received their first treatment) to 52 weeks (±6 weeks) post baseline
Average interval between AboBoNT-A injections throughout the observation period for focal ULS and/or LLS
Time frame: From baseline to 52 weeks (±6 weeks) post baseline
Average age at diagnosis of neurological condition
Time frame: Baseline
Average age at first AboBoNT-A injection
Time frame: Baseline
Average age at diagnosis of spasticity
Time frame: Baseline
Sex distribution (Male, Female)
Time frame: Baseline
Presence of underlying neurological condition: stroke, injury, chronic disease (multiple sclerosis, other)
Time frame: Baseline
Presence of location of spasticity (specify: right lower limb, left lower limb, right upper limb, left upper limb, unilateral, bilateral spasticity for lower and upper limb)
Data collected at index date up to 6 weeks prior to index date (when each patient received their first treatment)
Time frame: Baseline
Presence of previous spasticity-related treatments ongoing at index event, if available: antispasticity medications, pain medications and opioids, neurolytic agent, surgery, physiotherapy and occupational therapy
Time frame: Baseline
Presence of comorbidities: bowel conditions (irritable bowel syndrome, irritable bowel disease), urinary tract infections, chest infections, anxiety or depression, alcohol dependence/substance abuse.
Time frame: Baseline
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ipsen